血管内皮生长因子受体在眼眶海绵状畸形和淋巴管畸形中的表达
Vascular Endothelial Growth Factor Receptor Expression in Orbital Cavernous Malformations and Lymphatic Malformations.
作者信息
Tran Ann Q, Shoji Marissa K, Levitt Alexandra, Lee Wendy W
机构信息
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, FL.
Department of Ophthalmology, Manhattan Eye and Ear Throat Hospital, Northwell Health, New York, NY.
出版信息
Ophthalmol Vis Care. 2021;1(1). Epub 2021 Mar 31.
PURPOSE
To investigate the presence of vascular endothelial growth factor receptors (VEGFR) in orbital cavernous malformations and lymphatic malformations to further understand the feasibility of anti-VEGF treatment.
METHODS
This study was a single-center retrospective chart review performed at the Bascom Palmer Eye Institute of patients who underwent surgical excision of orbital cavernous malformations and lymphangiomas from 2000 - 2017. Immunohistochemical staining of these lesions for VEGFR1 and VEGFR2 expression was performed.
RESULTS
A total of 25 patients were identified with cavernous malformations (n=15) and lymphatic malformations (n=10). Ten specimens (7 cavernous malformations, 3 lymphatic malformations) underwent further immunohistochemical analysis. Six of 7 cavernous malformations and one of 3 lymphatic malformations stained positive for VEGFR1 and VEGFR2.
CONCLUSIONS
Both cavernous malformations and lymphatic malformations appear to express VEGFR with varying frequency. Additional studies are needed to better characterize the pathogenesis of these lesions, nature of VEGFR expression, and potential efficacy of anti-VEGF treatment.
目的
研究眼眶海绵状畸形和淋巴管畸形中血管内皮生长因子受体（VEGFR）的存在情况，以进一步了解抗VEGF治疗的可行性。
方法
本研究是在巴斯科姆帕尔默眼科研究所进行的一项单中心回顾性病历审查，研究对象为2000年至2017年间接受眼眶海绵状畸形和淋巴管瘤手术切除的患者。对这些病变进行VEGFR1和VEGFR2表达的免疫组织化学染色。
结果
共确定25例患者患有海绵状畸形（n = 15）和淋巴管畸形（n = 10）。10个标本（7个海绵状畸形，3个淋巴管畸形）进行了进一步的免疫组织化学分析。7个海绵状畸形中的6个和3个淋巴管畸形中的1个VEGFR1和VEGFR2染色呈阳性。
结论
海绵状畸形和淋巴管畸形似乎都以不同频率表达VEGFR。需要进一步研究以更好地描述这些病变的发病机制、VEGFR表达的性质以及抗VEGF治疗的潜在疗效。
Zotero 插件